| Identification | Back Directory | [Name]
luteolin-7-glucuronide | [CAS]
29741-10-4 | [Synonyms]
MXCS7PTTQS
Luteolin-7-O-glucuronide
Luteolin-7-β-D-glucuronide
Luteolin-7-O-β-D-glucuronide
Luteolin-7-beta-D-glucuronide
Luteolin 7-O-beta-glucuronide
luteolin-7-glucuronide USP/EP/BP
luteolin7-O-β-D-glucosiduronicaci
Cyanidenon-7-O-β-D-glucuronic acid
Luteolin 7-O-β-D-glucuronopyranoside
Luteolin 7-O-beta-glucuronopyranoside
Luteolin 7-O-beta-D-glucuronopyranoside
luteolin 7-O-beta-D-glucosiduronic acid
Luteolin 7-O-glucuronide (Luteolin 7-glucuronide4)
3′,4′,5,7-Tetrahydroxy-7-β-D-glucopyranuronoside flavone
Luteolin 7-O-glucuronide (Synonyms: Luteolin 7-glucuronide)
b-D-Glucopyranosiduronic acid,2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-1-benzopyran-7-yl
2-(3,4-Dihydroxyphenyl)-5-hydroxy-4-oxo-4H-1-benzopyran-7-yl-β-D-glucopyranosiduronic acid
β-D-Glucopyranosiduronic acid, 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-1-benzopyran-7-yl | [Molecular Formula]
C21H18O12 | [MDL Number]
MFCD04039811 | [MOL File]
29741-10-4.mol | [Molecular Weight]
462.36 |
| Chemical Properties | Back Directory | [Melting point ]
242-244℃ | [Boiling point ]
892.5±65.0 °C(Predicted) | [density ]
1.810±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
2.73±0.70(Predicted) | [color ]
Pale Yellow to Light Yellow | [Stability:]
Hygroscopic | [InChIKey]
VSUOKLTVXQRUSG-DAZJWRSOSA-N | [SMILES]
O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H]1O)C(O)=O)Oc2cc(O)c3C(=O)C=C(Oc3c2)c4ccc(O)c(O)c4 |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from bitter dish. | [Uses]
Luteolin- 7-?O-Glucuronide is a compound displaying strong anti-oxidant activity. | [Definition]
ChEBI: A luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 7-position. | [in vivo]
Luteolin 7-O-glucuronide (0.3-3 mg/kg, p.o., once daily for 5 days) improves depression-like and stress coping behaviors in the tail suspension test and forced swimming test in a mouse sleep deprivation model[3].
| Animal Model: | mouse sleep deprivation model[3] | | Dosage: | 0.3-3 mg/kg | | Administration: | p.o., once daily for 5 days | | Result: | Reduced the increased immobility time in sleep-deprived mice.
Reduced the increased plasma corticosterone level.
Reduced TNF-α and IL-1β level and increased BDNF mRNA expression in the hippocampus of sleep-deprived mice. |
| [IC 50]
MMP-1: 17.63 μM (IC50); MMP-3: 7.99 μM (IC50); MMP-8: 11.42 μM (IC50); MMP-9: 12.85 μM (IC50); MMP13: 0.03 μM (IC50) |
|
|